|
 South Korea’s GC Biopharma Corp. announced on Tuesday that its primary immune deficiency treatment, Alyglo, has been added to the formularies of three major U.S. health insurance companies.
Alyglo is a 10 percent intravenous immunoglobulin (IVIG) treatment that received U.S. Food and Drug Administration (FDA) approval in December last year.
The inclusion of Alyglo in these formularies is part of GC Pharma’s broader efforts to penetrate the U.S. market. The company previously signed contracts with six U.S. pharmacy benefit managers (PBMs) and group purchasing organizations (GPOs), including Express Scripts Inc. (ESI), one of the three largest PBMs in the country.
Additionally, partnerships with specialty pharmacies have been finalized.
Alyglo now has access to 80 percent of private insurance policyholders in the U.S., reaching its original market penetration goal.
|
|
